- Home
- NKTR
NKTR
Nektar Therapeutics
as 08-29-2025 4:00pm EST
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 508.2M | IPO Year: | 1994 |
| Target Price: | $81.67 | AVG Volume (30 days): | 642.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.48 - $37.38 | Next Earning Date: | 08-07-2025 |
| Revenue: | $74,934,000 | Revenue Growth: | -19.56% |
| Revenue Growth (this year): | -55.97% | Revenue Growth (next year): | -4.33% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Aug 19 '25 | Sell | $26.59 | 676 | $17,974.84 | 20,312 | |
| ROBIN HOWARD W | NKTR | President & CEO | Aug 19 '25 | Sell | $26.59 | 1,573 | $41,826.07 | 69,340 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Aug 19 '25 | Sell | $26.59 | 725 | $19,277.75 | 19,668 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Motley Fool
2 months ago
Why Nektar Therapeutics Stock Was Red-Hot Today
TipRanks
2 months ago
Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data
Zacks
2 months ago
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Investor's Business Daily
2 months ago
Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment
MT Newswires
2 months ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
2 months ago
BTIG Raises Nektar Therapeutics' Price Target to $100 From $60, Buy Rating Maintained
MT Newswires
2 months ago
Top Midday Gainers
MT Newswires
2 months ago
Sector Update: Health Care Stocks Higher in Afternoon Trading
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.